Evaluation of the prevention, treatment and synergistic activity between Helicobacter pylori IgY antibodies and pantaprazole on AGS cell line and C57BL/6 Mice.

Background and objectives: The growing resistance of Helicobacter pylori to antibiotics poses significant challenges in managing gastric ulcers. The application of IgY antibodies against H. pylori is a promising strategy. The current study evaluated the preventive and synergistic effects of IgY antibodies in conjunction with pantoprazole for treating H. pylori infection.

Materials and methods: This investigation specifically focused on the inhibitory effects of IgY in the AGS cell line infected with H. pylori. In addition, the synergistic activity of IgY with pantoprazole and its preventive and therapeutic effects were assessed in male C57BL/6 mice.

Results: The findings indicated that IgY antibodies possess a substantial inhibitory effect on the adhesion of H. pylori to the AGS cell line. Furthermore, IgY antibodies resulted in a significant reduction (P<0.05) in the population of H. pylori and the severity of gastritis in infected C57BL/6 mice in both treatment and prevention groups. Notably, the optimal outcome was observed when IgY was administered alongside pantoprazole.

Conclusion: The use of IgY has the potential to repair damaged cells and prevent infection by decreasing bacterial adherence to gastric epithelial cells. Given its synergistic effect with pantoprazole, IgY can be recommended as a suitable complementary treatment in conjunction with pantoprazole.